Myomo, Inc. (MYO) Q2 2025 Earnings Conference Call Transcript

Myomo, Inc. reported Q2 2025 revenue of $9.7 million, a 28% year-over-year increase, driven by higher unit volume and average selling price, but experienced a significant increase in operating expenses (up 65%) and a net loss of $4.6 million. The company faced operational challenges including lower lead quality from Facebook, which increased cost per pipeline add to $2,900, and persistent low authorization rates from Medicare Advantage plans. In response, Myomo is shifting advertising spend to television, implementing an 8% U.S. workforce reduction for $2 million in annual savings, and aggressively appealing Medicare Advantage denials. Despite these headwinds, the company is expanding its O&P channel and clinical referral programs, and revised its full-year 2025 revenue guidance to $40-$42 million (23-29% growth), maintaining confidence in its path to sustainable cash flow positive operations.

Analysis

Myomo, Inc. reported a 28% year-over-year revenue increase to $9.7 million for Q2 2025, but this top-line growth was significantly undermined by deteriorating operational metrics and profitability. The net loss widened substantially to $4.6 million from a $1.1 million loss in the prior-year quarter, while operating expenses surged 65%, driven by a 162% increase in advertising spend. The core issue stems from a challenged patient acquisition funnel; lower-quality leads from Meta's platform nearly doubled the cost per pipeline add to $2,900 from approximately $1,500 in recent quarters. This inefficiency is compounded by persistent pre-authorization denials from Medicare Advantage plans, which represent 61% of the patient pipeline and necessitate a lengthy, resource-intensive appeals process. Management has responded by reducing its U.S. workforce by 8% for an expected $2 million in annual savings and shifting advertising from social media to television, anticipating higher-quality leads. Reflecting these headwinds, the company revised its full-year revenue guidance down to $40-$42 million, representing 23-29% growth, with a flat sequential forecast for Q3, signaling that near-term pressures will persist despite management's corrective actions.

Key Decisions for Investors

• Investors should scrutinize the cost per pipeline add and Medicare Advantage authorization rates in subsequent quarters, as improvement in these metrics is critical to validating management's new advertising strategy and path to profitability.
• Given the normalized Q2 cash burn of $4.9 million against a $15.5 million cash balance, closely monitor the company's liquidity and progress on its $2 million cost-saving plan to ensure its 12-month operational runway remains intact.
• The downward revision of full-year revenue guidance suggests significant near-term risk, and it may be prudent to await tangible evidence of a turnaround in lead conversion and authorization rates before building or adding to a position.
• Pay close attention to growth in the O&P and clinical referral channels, as success here could diversify lead sources away from the challenged direct-to-consumer advertising model and provide a more stable, cost-effective path to growth.